Publications 2017-12-06T10:14:49+00:00

DiviTum® Publications

Breast Cancer

  • Bagegni N, Thomas S, Liu N et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res and Treat. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

    Read more

  • Bjohle J, Bergqvist J, Gronowitz JS et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res and Treat 2013;139(3):751-8.

    Read more

  • Nisman B, Kadouri L, Allweis T et al. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5.

    Read more

  • Nisman B, Allweis T, Kadouri L et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010;7(2):65-72.

    Read more

Lung Cancer

  • Nisman B, Nechushtan H, Biran H et al. Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients. J Thorac Oncol 2014 Oct; 9(10):1568-1572.

    Read more

  • Korkmaz T, Seber S, Okutur K et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers 2013 Feb;18(1):88-94.

    Read more

Pancreatic Cancer

  • Felix K, Hinz U, Dobiasch S, Hackert T el al. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas. 2017 Nov 16. doi: 10.1097. [Epub ahead of print]

    Read more

Breast and Colorectal Cancer

  • Bolayirli M, Papila C, Korkmaz GG et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal. 2013 May;27(3):220-6.

    Read more

Renal Cell Carcinoma

  • Nisman B, Appelbaum L, Yutkin V et. al. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver. Anticancer Res. 2016 Apr;36(4):1791-7.

    Read more

  • Nisman B, Yutkin V, Nechushtan H et al. Circulating Tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nefrectomy. Urology 76 (2), 513. e1-e6, 2010.

    Read more

Blood Malignancies

  • Stelmach P, Blonski JZ, Wawrzyniak E et al. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw. 2016, 70(0):1321-1330.

    Read more

  • Bacovsky J, Myslivecek M, Minarik J et al. Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance – comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):135-8.

    Read more

  • Procházka V, Faber E, raida L, et al.  High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma. 2012 Jul;53(7):1306-10.

    Read more

  • Rivkina A, Vitols G, Murovska M et al. Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels. Exp.  Oncology 2011:33(2), 99-103.

    Read more

Method

  • Nisman B, Allweis T, Kadouri L et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med. 2013 ;51(2):439-47.

    Read more

Biovica Perspectives on Biomarkers

Perspective on Biomarkers covers important aspects of the use of biomarkers and has a primary focus on the use and applications of DiviTum™. The opportunities to provide improved tools for evaluating the efficacy of new oncology compounds and predict their efficacy are explored.

Pharmaceutical companies need to find not only good targets for therapies and good candidate drugs for these targets, they also need techniques to provide accurate and clinically meaningful data on the efficacy of these drugs. These techniques are what Biovica is developing and Perspective on biomarkers presents.

Biovica Perspectives on Biomarkers 1:1 Download PDF
Biovica Perspectives on Biomarkers 1 Download PDF